Outlook Therapeutics, Inc.

NASDAQ:OTLK

Biotechnology

Healthcare
$0.41 -5.76%

-$0.10 today

Market cap
$99.30M
Beta
0.98
P/E (TTM)
-2.1
EPS (TTM)
-$0.74
52W Low $0.16High $3.39

Volume 4.42M

Average 17.46M

OTLK Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Outlook Therapeutics, Inc.NASDAQ: OTLK

Stock-Based Compensation · Q2 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q2 FY2026 stock-based compensation of $757.48K fell 56.0% year over year, behind the -37.3% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 14.0% from the prior quarter. Over 3 fiscal years it compounded at +4.9% a year.

Context

  • Stock-based compensation amounted to 629.5% of revenue in FY2025.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -56.0% toward the trailing-twelve-month pace of -37.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$757.48K-14.0% QoQ
Last fiscal yearSep 2025
$8.9M+65.2% YoY
LTMMar 2026
$5.14M-37.3% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-56.0%——
1 year+65.2%——
3-year CAGR+4.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
8.9M USD
Year-over-year change
+65.2%
4-year CAGR
+16.2%

Stock-Based Compensation vs competitors

How OTLK compares with its peers on the latest reported figures

  • OTLK's LTM Mar 2026 stock-based compensation of $5.14M is the 3rd largest of the 9 companies compared; the peer median is $3.09M.
  • Its year-over-year change of -37.3% is the 6th highest of 9, against a peer median of -29.9%.
  • Stock-based compensation amounts to 1543.3% of revenue for OTLK, versus a peer median of 17.0%.
OTLK Competitors Peer median
Stock-Based Compensation for OTLK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OSTXOS Therapies IncorporatedLTM Mar 2026$4.27B +453006.6%——
IPSCCentury Therapeutics, Inc.LTM Mar 2026$5.86M -50.8%-13.8%—
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$5.14M -37.3%+4.9%1543.3%
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026$3.79M -50.8%-5.5%18.1%
CUECue Biopharma, Inc.LTM Mar 2026$3.45M -44.6%-20.7%10.6%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$2.72M -37.2%-10.8%—
EQEquillium, Inc.LTM Mar 2026$2.63M -22.6%-21.7%—
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$1.82M +13.4%—128.8%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$367K +43.4%-60.2%16.0%
Peer median (excluding OTLK) $3.09M-29.9%-17.2%17.0%

Competitors are the stored peer set for OTLK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income(53.16M)(66.05M)(58.98M)(75.37M)(62.42M)
Depreciation & Amortization262.14K204.69K44.19K113.86K117.05K
Deferred Income Tax498.49K0000
Stock-Based Compensation4.89M7.71M5.55M5.39M8.9M
Change in Working Capital(7.08M)(1.68M)4.75M(3.02M)4.86M
Accounts Receivables0000(1.49M)
Inventory0000(3.34M)
Accounts Payables(198.47K)1.3M3.08M1.39M1.67M
Other Working Capital(6.88M)(2.98M)1.67M(4.41M)8.02M
Other Non-Cash Items341.55K3.15M5.66M4.09M1.58T
Operating Cash Flow(54.25M)(56.67M)(42.97M)(68.79M)(51.83M)
Capital Expenditures0000(3)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment6.31M(2.32M)19.77M(4.27K)(3.04M)
Common Stock Issued46.3M62.31M30.02M60.33M48.03M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.59M(394.15K)(823.89K)044.98T
Financing Cash Flow56.19M59.59M48.97M60.33M44.98M
Effect of Forex Changes00000
Net Change in Cash1.94M2.92M6M(8.46M)(6.84M)
Free Cash Flow(54.25M)(56.67M)(42.97M)(68.79M)(51.83M)

Outlook Therapeutics, Inc.

NASDAQ:OTLK

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.